Trial Profile
Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):Two Stage, Phase I/II Trail
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2020
Price :
$35
*
At a glance
- Drugs Camrelizumab (Primary) ; Decitabine (Primary) ; Doxorubicin; Gemcitabine; Vinorelbine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 04 Jun 2020 Status changed from recruiting to completed as per results published in the Clinical Cancer Research.
- 04 Jun 2020 Results published in the Clinical Cancer Research
- 29 Nov 2018 Treatment arms has been changed fro 2 to 1 and study design has been changed from Parallel Assignment to Single Group Assignment.